2Istvan ES,Deisenhofer J.Structural mechanism for statin inhibition of HMG-CoA reductase [J].Science,2001,292(5519):1160-1164.
3Mammen AL,Amato AA.Statin myopathy:a review of recent progress[J].Current Opinion in Rheumatology,2010,22(6):644-650.
4Sniderman AD.Is there value in liver function test and creatine phosphokinase monitoring with stat in use? [J].The American Journal of Cardiology,2004,94(9):30-34.
5Beltowski J,Wojcicka G,Iamroz-Wisniewska A.Adverse effects of statins-mechanisms and consequences [J].Current Drug Safety,2009,4(3):209-228.
6Shen L,Shah BR,Reyes EM,et al.Role of diuretics,blockers,and statins in increasing the risk of diabetes in patients with impaired glucose tolerance:reanalysis of data from the NAVIGATOR study[J].BMJ:British Medical Journal,2013,347.
7Ridker PM,Pradhan A,MacFadyen JG,et al.Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial [J].The Lancet.2012.3S0(9S41):565-57l.
8Ganesan S.Ito MK.Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-Ll adipocytes[J].Metabolic Syndrome and Related Disorders.2013.11(4):251-255.
9Kimura S.Inoguchi T.Yokomizo H.et al.Randomized comparison of pita vasta tin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy[J].Diabetes.Obesity and Metabolism.2012.14(7):666-669.
10J Colhoun HM.Betteridge DJ.Durrington PN.et al.Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes:an analysis from the Collaborative Atorvastatin Diabetes Study(CARDS)[J].American Journal of Kidney Diseases.2009.54(5):S10-S19.
